Compare StocksABBV vs ABT

AbbVie Inc. (ABBV) vs Abbott Laboratories (ABT): Which Is the Better Buy in 2026?

As of 2026-06-19, ABBV is overvalued at $216, with a DCF intrinsic value of $160 and a margin of safety of -35%. ABT is fairly valued at $88, with an intrinsic value of $93 and a margin of safety of 5%. Of the two, ABT has the wider margin of safety.

ABBV
AbbVie Inc.
$216.49
VS
ABT
Abbott Laboratories
$88.41

Rewards

ABBV
  • AbbVie Inc. has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
  • Gross margin of 72.0% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • AbbVie Inc. scores 82/100 on the Economic Moat Score (Wide Moat), with reinvestment efficiency as the strongest competitive dimension.
ABT
  • Abbott Laboratories scores 86/100 on the Economic Moat Score (Wide Moat), with margin stability as the strongest competitive dimension.
  • Insiders have bought $1.1M worth of stock in the past 3 months — significant skin in the game.
  • Altman Z-Score of 5.60 indicates very low bankruptcy risk — the company is firmly in the safe zone.

Risks

ABBV
  • Buybacks have been poorly timed — 3 out of 4 years involved repurchases at relatively expensive valuations.
  • FCF yield of 5.4% suggests reasonable valuation assuming continued moderate growth.
  • Trailing P/E of 105.6x is 69% above the historical average of 62.3x — the stock trades at a premium to its own history.
ABT

    Key Valuation Metrics

    Learn more →
    ABBV
    ABT
    Valuation
    $20.81B
    Free Cash Flow
    $6.34B
    5.44%
    FCF Yield
    4.12%
    105.60
    Trailing P/E
    24.76
    13.32
    Forward P/E
    14.59
    Quality & Moat
    21.89%
    ROIC
    5.53%
    N/A
    ROE
    12.33%
    72.03%
    Gross Margin
    56.50%
    0.61
    PEG Ratio
    1.34
    Balance Sheet Safety
    N/A
    Net Debt / Equity
    0.51
    N/A
    Interest Coverage
    N/A
    2.12
    Net Debt / EBITDA
    2.29
    3.11%
    Dividend Yield
    2.76%
    ABBV: 8Ties: 1ABT: 1
    ABBVABT

    Historical Fundamentals

    Learn more →
    ABBV

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    ABT

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    $1 Retained Earnings Test

    Learn more →
    ABBV
    N/A
    Net losses over 3 years — test not applicable
    Company had negative cumulative retained earnings
    Σ Retained
    $-19.85B
    Δ Market Cap
    +$118.02B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    ABT
    $1.89
    created per $1 retained over 3 years
    Value Creator
    Σ Retained
    $14.14B
    Δ Market Cap
    +$26.79B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    ABBV
    35.3% Overvalued
    Price is 35.3% above estimated fair value
    Current Price: $216.49
    Fair Value: $160.05
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    ABT
    4.8% Margin of Safety
    Price is 4.8% below estimated fair value
    Current Price: $88.41
    Fair Value: $92.91
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    ABBV

    What growth rate is the market pricing in at $216?

    +17.1%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +8.7%

    The market implies +17.1% Owner Earnings growth, above historical trends.

    Standard FCF implies a demanding +8.7%, reflecting heavy growth investment.

    ABT

    What growth rate is the market pricing in at $88?

    +10.3%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +12.5%

    The market implies +10.3% Owner Earnings growth, above historical trends.

    Standard FCF implies a demanding +12.5%, reflecting heavy growth investment.

    Economic Moat Score

    Learn more →
    ABBV
    82/100
    Wide Moat
    70+ Wide · 40-69 Narrow · <40 None

    Wide moat with strength across all dimensions. Reinvestment Efficiency is the standout factor.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
    ABT
    86/100
    Wide Moat
    70+ Wide · 40-69 Narrow · <40 None

    Wide moat with strength across all dimensions. Margin Stability is the standout factor.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

    Forensic Accounting

    Learn more →
    ABBV
    -2.86
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
    ABT
    -2.48
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    ABBV
    Insiders 0.1%Institutions 76.9%Retail & Other 23.0%
    No. of Institutional Holders5,106
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    ABT
    Insiders 0.5%Institutions 82.7%Retail & Other 16.8%
    No. of Institutional Holders3,953
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    ABBV
    0
    Buys (3M)
    0
    Buys (12M)
    No open market insider purchases found.
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    ABT
    2
    Buys (3M)
    4
    Buys (12M)
    Total value (12M): $4.23M
    STARKS DANIEL J
    Director
    $926,537
    @ $92.65 · 2026-04-27
    BOUDREAU PHILIP P
    Chief Financial Officer
    $201,300
    @ $91.50 · 2026-04-23
    STARKS DANIEL J
    Director
    $1.09M
    @ $108.73 · 2026-02-04
    FORD ROBERT B.
    Chief Executive Officer
    $2.01M
    @ $107.13 · 2026-01-23
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    ABBV
    0
    Sells (3M)
    5
    Sells (12M)
    Total value (12M): $21.79M
    PURDUE DAVID R.
    Officer
    $1.22M
    @ $233.56 · 2026-03-04
    SIATIS PERRY C.
    General Counsel
    $4.38M
    @ $234.39 · 2026-03-02
    SIATIS PERRY C.
    General Counsel
    $5.15M
    @ $230.00 · 2026-02-25
    SALEKI-GERHARDT AZITA
    Chief Operating Officer
    $8.41M
    @ $198.42 · 2025-08-12
    DONOGHOE NICHOLAS
    Officer
    $2.64M
    @ $198.51 · 2025-08-05
    STEWART JEFFREY RYAN
    Officer
    $12.36M
    @ $210.08 · 2025-03-31
    REENTS SCOTT T.
    Chief Financial Officer
    $3.75M
    @ $212.34 · 2025-03-14
    GONZALEZ RICHARD A
    Director
    $20.26M
    @ $205.45 · 2025-03-03
    SIATIS PERRY C.
    General Counsel
    $5.82M
    @ $208.69 · 2025-03-03
    RICHMOND TIMOTHY J
    Officer
    $4.47M
    @ $210.45 · 2025-03-03
    BUCKBEE KEVIN K
    Officer
    $3.85M
    @ $203.41 · 2025-02-26
    RICHMOND TIMOTHY J
    Officer
    $6.07M
    @ $202.90 · 2025-02-26
    SIATIS PERRY C.
    General Counsel
    $1.14M
    @ $197.90 · 2025-02-20
    BUCKBEE KEVIN K
    Officer
    $310,032
    @ $172.24 · 2024-12-16
    GONZALEZ RICHARD A
    Officer and Director
    $12.40M
    @ $186.52 · 2024-08-05
    GONZALEZ RICHARD A
    Officer and Director
    $49.50M
    @ $175.00 · 2024-07-17
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    ABT
    0
    Sells (3M)
    8
    Sells (12M)
    Total value (12M): $1.44M
    SALVADORI DANIEL GESUA SIVE
    Officer
    $102,288
    @ $115.58 · 2026-03-02
    MCCOY JOHN A. JR
    Officer
    $67,614
    @ $115.58 · 2026-03-02
    MORRONE LOUIS H
    Officer
    $132,224
    @ $115.58 · 2026-03-02
    SHROFF ERIC
    Officer
    $81,946
    @ $115.58 · 2026-03-02
    CUSHMAN ELIZABETH C
    General Counsel
    $30,398
    @ $115.58 · 2026-03-02
    MORELAND MARY K
    Officer
    $70,851
    @ $115.58 · 2026-03-02
    SHROFF ERIC
    Officer
    $203,043
    @ $128.02 · 2025-11-25
    BOUDREAU PHILIP P
    Chief Financial Officer
    $746,758
    @ $134.55 · 2025-08-08
    BLOUNT SALLY E
    Director
    $337,116
    @ $129.66 · 2025-04-30
    EARNHARDT LISA D
    President
    $12.23M
    @ $133.83 · 2025-03-07
    MCCOY JOHN A. JR
    Officer
    $77,652
    @ $138.17 · 2025-03-03
    SHROFF ERIC
    Officer
    $77,652
    @ $138.17 · 2025-03-03
    MORELAND MARY K
    Officer
    $109,292
    @ $138.17 · 2025-03-03
    MORRONE LOUIS H
    Officer
    $153,507
    @ $138.17 · 2025-03-03
    WAINER ANDREA F
    Officer
    $131,123
    @ $138.17 · 2025-03-03
    FORD ROBERT B.
    Chief Executive Officer
    $37.44M
    @ $131.17 · 2025-02-05
    SALVADORI DANIEL GESUA SIVE
    Officer
    $3.05M
    @ $128.50 · 2025-01-30
    ALLEN HUBERT L.
    Officer
    $24.34M
    @ $128.26 · 2025-01-30
    ALLEN HUBERT L.
    Officer
    $18.42M
    @ $117.04 · 2024-10-21
    FORD ROBERT B.
    Chief Executive Officer
    $16.49M
    @ $116.41 · 2024-09-12
    MCCOY JOHN A. JR
    Officer
    $3,100
    @ $114.81 · 2024-09-04
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    ABBV
    FearGreed
    😐Neutral(56/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    ABT
    FearGreed
    😐Neutral(41/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    ABBV
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (56)
    ABT
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (41)
    View ABBV Full AnalysisView ABT Full Analysis

    Frequently Asked Questions: ABBV vs ABT

    Is AbbVie Inc. or Abbott Laboratories more undervalued in 2026?

    Based on our discounted cash flow model, ABT trades at a 4.8% margin of safety (intrinsic value $93 vs. price $88), compared to ABBV's -35.3% margin of safety (intrinsic $160 vs. $216).

    Which stock has a wider economic moat, AbbVie Inc. or Abbott Laboratories?

    ABT scores 86/100 (Wide moat), while ABBV scores 82/100 (Wide moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

    Is AbbVie Inc. in financial distress?

    ABBV's Altman Z-Score of 2.4 places it in the Grey zone, signaling elevated bankruptcy risk. ABT scores 5.6 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

    Which company has better free cash flow, AbbVie Inc. or Abbott Laboratories?

    AbbVie Inc. (ABBV) generates a 5.4% free cash flow yield, compared to Abbott Laboratories's 4.1%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

    Which stock has higher return on invested capital, AbbVie Inc. or Abbott Laboratories?

    ABBV earns 21.9% ROIC versus ABT's 5.5%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

    Which dividend is safer, AbbVie Inc.'s or Abbott Laboratories's?

    ABT's dividend earns a safety score of 84/100 (Very Safe), compared to ABBV's 39/100 (Unsafe). ABT has raised its dividend for 3 consecutive years.

    ABBV vs ABT: Which Is the Better Buy in 2026? | SafetyMargin.io